The state of Illinois currently has 57 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Recruiting
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Foot & Ankle Center of Illinois, Springfield, Illinois
Conditions: Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Type 1 Diabetes, Obesity, Overweight
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
Recruiting
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2025
Locations: Northwestern Organ Transplant Center, Chicago, Illinois +1 locations
Conditions: Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment. Study details include: Screening period: at least 3 weeks and up to 5 weeks Double-blind treatment period (104 weeks): * Main treatment period: 52 weeks * Blinded extension: 52 weeks Safety follow-up: up to 26 weeks The treatment duration wil... Read More
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
05/22/2025
Locations: NorthShore University HealthSystem - Skokie- Site Number : 8400007, Skokie, Illinois
Conditions: Type 1 Diabetes Mellitus
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/21/2025
Locations: Alliance For Multispecialty Research - Oak Brook, Oak Brook, Illinois +2 locations
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Diabetes Toolkit at Discharge
Recruiting
The purpose of this randomized clinical trial is to implement the DM Discharge Toolkit into hospital discharge and assess the effect of the DM Discharge Toolkit on patients newly requiring insulin.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/20/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Mechanisms of Prediabetic States in Sleep Apnea
Recruiting
The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
05/19/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Sleep Apnea, Pre-diabetes
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Chicago Medicine, Chicago, Illinois +2 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Cook County Health, Chicago, Illinois +3 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Enhancing Diabetes Care: Exposome &Amp; Sensors
Recruiting
The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/16/2025
Locations: University of Illinois - Chicago, Chicago, Illinois +1 locations
Conditions: Type 2 Diabetes
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
05/12/2025
Locations: Northshore University Health System, Evanston, Illinois
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: Research Site, Chicago, Illinois +1 locations
Conditions: Endocrinology, Diabetes, Type II, Obesity